<unk>  is known to interact with: * Alcohol. Increased sedative effect. * Altretamine. Risk of severe drop in blood pressure upon standing. * Analgesics (painkillers). Increased risk of ventricular arrhythmias. * Anticoagulants (blood thinners).<unk>  may inhibit the metabolism of certain anticoagulants leading to a potentially increased risk of bleeding. * Anticonvulsants. Possibly reduce the anticonvulsant effect of antiepileptics by lowering the seizure threshold. * Antihistamines. Possible increase of antimuscarinic (potentially increasing risk of paralytic ileus, among other effects) and sedative effects. * Antimuscarinics. Possible increase of antimuscarinic side-effects. * Anxiolytics and hypnotics. Increased sedative effect. * Apraclonidine. Avoidance advised by manufacturer of apraclonidine. * Brimonidine. Avoidance advised by manufacturer of brimonidine. * Clonidine.<unk>  may reduce the antihypertensive effects of clonidine. * Diazoxide. Enhanced hypotensive (blood pressure-lowering) effect. * Digoxin. May increase risk of irregular heart rate. * Disulfiram. May require a reduction of<unk>  dose. * Diuretics. Increased risk of reduced blood pressure on standing. * Cimetidine, diltiazem, verapamil. May increase concentration of<unk>  in the blood plasma. * Hydralazine. Enhanced hypotensive effect. * Monoamine oxidase inhibitors (MAOIs). Advised not to be started until at least 2 weeks after stopping MAOIs. MAOIs are advised not to be started until at least 1–2 weeks after stopping TCAs like<unk> . * Moclobemide. Moclobemide is advised not to be started until at least one week after treatment with TCAs is discontinued. * Nitrates. Could possibly reduce the effects of sublingual tablets of nitrates (failure to dissolve under tongue owing to dry mouth). * Rifampicin. May accelerate<unk>  metabolism thereby decreasing plasma concentrations of<unk> . * Ritonavir. May increase<unk>  concentration in the blood plasma. * Sodium nitroprusside. Enhanced hypotensive effect. * Thyroid hormones. Effects on the heart of<unk>  may be exacerbated.
Lofepramine
Diphenhydramine
Sibutramine
Dezocine
Palonosetron
Zotepine
Avacopan
Quinupramine